Addiction | MediciNova, Inc.

2023.06.29 MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

AddictionMN-166clinical trials

2023.01.30 MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder

AddictionMN-166clinical trials

2022.04.08 MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research

AddictionMN-166treatise

2022.02.22 MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs

AddictionMN-166treatise

2022.01.27 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe

AddictionMN-166patents

2021.06.21 MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal

AddictionMN-166treatise

2020.08.06 MediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN‑166 (ibudilast) in Alcohol Use Disorder at the American Psychological Association 2020 Annual Convention

AddictionMN-166academic conference

2018.08.21 米国国立アルコール摂取障害・依存症研究所（National Institute of Alcohol Abuse and Alcoholism, NIAAA）からのR01研究助成金授与のお知らせ～MN-166のアルコール摂取障害を対象とするフェーズ2b臨床治験～

AddictionMN-166clinical trials

2018.05.08 MN-166のアルコール摂取障害および離脱症を適応とするUCLAとの共同臨床治験開始のお知らせ

AddictionMN-166clinical trials

2018.03.29 MN-166のメタンフェタミン（覚醒剤）依存症を適応とするフェーズ2臨床治験結果のお知らせ

AddictionMN-166clinical trials

2017.11.10 MN-166 のメタンフェタミン(覚醒剤)依存患者を対象とするバイオマーカー臨床治験開始のお知らせ

AddictionMN-166clinical trials

2017.02.07 第50回冬季脳研究学会におけるメタンフェタミン（覚醒剤）依存症を適応とするMN-166のフェーズ1b臨床治験で得られた新たな知見発表のお知らせ

AddictionMN-166clinical trials

2017.01.24 アルコール依存症を適応とするMN-166に関する論文掲載のお知らせ